Clinical trials
Cardiomyopathies clinical trials
Below are recruiting cardiomyopathies clinical trials, each written for real people, not researchers. We’re tracking 322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07515235Recruiting
DMD Gene Variants and Heart Function in Young Males
This study examines how different genetic changes in the DMD gene affect heart function in boys with dystrophinopathy (a muscle-weakening condition). Understanding this connection may help doctors better monitor and treat heart problems in affected boys.
ThessalonikiAges 2–24 - NCT06477042Recruiting
Act on quality of life in patients with aortic stenosis
This trial studies how a TAVI procedure affects the quality of life of people with aortic stenosis, especially those with multiple health conditions. It may help doctors understand how this treatment improves daily living for patients like you.
Clermont-FerrandAges 18 years+ - NCT07464132RecruitingPhase 1/Phase 2
New PET scan for detecting certain diseases
This trial uses a special PET scan tracer to see if it can help find and monitor diseases linked to a protein called FAP. It is for both cancer patients needing a biopsy and healthy volunteers.
Beijing, Beijing MunicipalityAges 18–85 - NCT07454135Recruiting
Studying heart muscle disease and atrial fibrillation
This trial looks at how the heart's electrical signals work in people with hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened) who also have atrial fibrillation (a type of irregular heartbeat). The goal is to understand these signals better during a planned ablation procedure, which is a treatment to fix the irregular rhythm.
LondonAges 18–80 - NCT07448623RecruitingPhase 1
Testing coramitug for ATTR amyloid heart disease
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
GroningenAges 60 years+ - NCT06228924RecruitingPhase 1
Gene therapy for ARVC with PKP2 mutation
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
San Francisco, CaliforniaAges 18–65 - NCT07358078Recruiting
Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Tucson, ArizonaAges 18 years+ - NCT07360067Recruiting
Comparing two types of heart pacing for sick sinus syndrome
This study compares two different ways of placing a pacemaker lead to see which one better helps heart function and reduces future heart problems in people with sick sinus syndrome.
Seoul, SeoulAges 19 years+ - NCT07339007Enrolling by invitation
Validating a heart ultrasound training program for family doctors
This study tests whether a training program helps family doctors use a focused heart ultrasound (FoCUS) to assess patients. If you need a heart ultrasound as part of your regular care, you may be able to join.
Barcelona, CataloniaAges 15 years+ - NCT06866912Recruiting
Observational study of amyloidosis and TTR gene carriers
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
BolognaAges 18–99 - NCT07322237RecruitingPhase 4
Study on heart function drugs for liver cirrhosis patients
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
ChandigarhAges 18–65 - NCT07314268Recruiting
Study of tiny blood particles in heart amyloidosis
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
São Paulo, São PauloAges 18 years+ - NCT07308704Recruiting
Using AI to spot heart muscle disease on echocardiograms
This study at Mayo Clinic is testing an artificial intelligence (AI) tool that analyzes echocardiograms (ultrasound of the heart) to find early signs of four types of heart muscle disease. If the AI flags a high-risk pattern, doctors can learn whether acting on that alert helps catch the condition sooner.
Rochester, MinnesotaAges 18 years+ - NCT05828719Recruiting
Compare heart stent treatment vs medicines for weak heart function
This study looks at whether opening blocked heart arteries with a stent (a PCI procedure) works better than staying on heart medicines for people with weakened pumping function and certain types of heart failure. It may help patients by testing which approach best improves outcomes over time.
SeoulAges 19 years+ - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT07286643Recruiting
Ultrasound-guided sepsis care for patients with cirrhosis
This study tests whether using a special ultrasound of the heart can guide treatment for sepsis-related low blood pressure in patients with cirrhosis. It aims to improve care and outcomes for critically ill patients.
ChandigarhAges 18–65 - NCT07265349RecruitingPhase 1/Phase 2
Stem cells plus bypass surgery for chronic heart failure
This trial tests whether injecting stem cells from umbilical cord tissue into the heart muscle during bypass surgery can improve heart function in people with chronic heart failure. It is for patients who are already scheduled for bypass surgery and have a weakened heart pump (LVEF between 21% and 40%).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06898723RecruitingPhase 4
Shenfu injection to prevent heart problems in sepsis
This trial tests whether Shenfu injection can help prevent heart muscle damage in people with septic shock. If you have septic shock, you may be able to join this study to see if this treatment helps protect your heart.
Wuhu, AnhuiAges 18 years+ - NCT05521451Recruiting
Study for adults with heart rhythm problems
This trial is a “clinical cohort” study, meaning it follows adults with certain heart rhythm issues to understand them better. Your participation may help researchers learn what to expect and how best to support people over time.
HamburgAges 18 years+ - NCT07223242RecruitingPhase 2/Phase 3
Tailored exercise training for heart failure with preserved pumping strength
This trial tests a personalized exercise program to help people with a type of heart failure called HFpEF. You may qualify if your heart still pumps well but you have trouble being active, and you are willing to use a phone app and exercise regularly.
Dallas, TexasAges 18 years+ - NCT06907186Recruiting
Psychological support program for amyloidosis patients and families
This study tests a structured psychological support program for people with hereditary transthyretin amyloidosis (ATTRv) with heart involvement, their caregivers, and those who carry the gene but have no symptoms yet. The goal is to see if the program is practical and well-accepted.
PaviaAges 18 years+ - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07196839Recruiting
Study of heart medication and amyloid levels over time
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
Dallas, TexasAges 30–80
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiomyopathies?
- Yes. Clin2 currently lists 322 recruiting cardiomyopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiomyopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.